Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced breast cancer: drug combo shows promise in shrinking tumors

NCT ID NCT04721977

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 20 times

Summary

This study tests a new drug called MK-7119 (tucatinib) combined with two standard drugs (trastuzumab and capecitabine) in 66 people with advanced HER2+ breast cancer that has stopped responding to previous treatments. The main goal is to see if the combination can shrink tumors. Participants must have already tried certain other therapies. The study is active but not recruiting new participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aichi Cancer Center Hospital ( Site 1013)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Fukushima Medical University Hospital ( Site 1012)

    Fukushima, 960-1295, Japan

  • Hiroshima City Hiroshima Citizens Hospital ( Site 1024)

    Hiroshima, 730-8518, Japan

  • Hokkaido University Hospital ( Site 1022)

    Sapporo, Hokkaido, 060-8648, Japan

  • Hyogo Cancer Center ( Site 1005)

    Akashi, Hyōgo, 673-8558, Japan

  • Hyogo College of Medicine Hospital ( Site 1019)

    Nishinomiya, Hyōgo, 663-8501, Japan

  • Juntendo University Hospital ( Site 1025)

    Tokyo, 113-0033, Japan

  • Kanagawa Cancer Center ( Site 1010)

    Yokohama, Kanagawa, 241-8515, Japan

  • Kumamoto Shinto General Hospital ( Site 1007)

    Kumamoto, 862-8655, Japan

  • Medical Corporation Nahanishikai Nahanishi Clinic ( Site 1016)

    Naha, Okinawa, 901-0154, Japan

  • Nagoya University Hospital ( Site 1021)

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital ( Site 1003)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 1002)

    Kashiwa, Chiba, 2778577, Japan

  • National Cheng Kung University Hospital ( Site 3000)

    Dawan, Tainan, 704, Taiwan

  • National Hospital Organization Hokkaido Cancer Center ( Site 1017)

    Sapporo, Hokkaido, 003-0804, Japan

  • National Hospital Organization Kyushu Cancer Center ( Site 1009)

    Fukuoka, 811-1395, Japan

  • National Hospital Organization Osaka National Hospital ( Site 1001)

    Osaka, 540-0006, Japan

  • National Hospital Organization Shikoku Cancer Center ( Site 1014)

    Matsuyama, Ehime, 791-0280, Japan

  • Osaka International Cancer Institute ( Site 1004)

    Osaka, 541-8567, Japan

  • Saitama Cancer Center ( Site 1018)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Samsung Medical Center ( Site 2002)

    Seoul, 06351, South Korea

  • Seoul National University Hospital ( Site 2003)

    Seoul, 03080, South Korea

  • Severance Hospital ( Site 2001)

    Seoul, 03722, South Korea

  • Showa University Hospital ( Site 1023)

    Tokyo, 142-8666, Japan

  • Social medical corporation Hakuaikai Sagara Hospital ( Site 1008)

    Kagoshima, 892-0833, Japan

  • The Cancer Institute Hospital of JFCR ( Site 1015)

    Tokyo, 135-8550, Japan

  • Tokyo Medical University Hospital ( Site 1006)

    Tokyo, 160-0023, Japan

  • University of Tsukuba Hospital ( Site 1020)

    Tsukuba, Ibaraki, 305-8576, Japan

Conditions

Explore the condition pages connected to this study.

BREAST CANCER